Ricerc@Sapienza

The discovery of the ferroportin-hepcidin complex has led to a critical review on the treatment of anemia and anemia of inflammation (AI). Ferroportin, the only known mammalian iron exporter from cells to blood, is negatively regulated by hepcidin, a hormone peptide able to bind to ferroportin, leading to its degradation. Therefore, new efficient therapeutic interventions acting on hepcidin and ferroportin are imperative to manage anemia and AI.

Micronutrient deficiencies are relatively common, in particular iron and cobalamin deficiency, and may potentially lead to life-threatening clinical consequences when not promptly recognized and treated, especially in elderly patients. The stomach plays an important role in the homeostasis of some important hematopoietic micronutrients like iron and cobalamin, and probably in others equally important such as ascorbic acid, calcium, and magnesium.

An impaired peak oxygen uptake (V̇O2peak) during a maximal cardiopulmonary exercise test (CPET) has been shown extensively to correlate with a poor prognosis in heart failure (HF) patients. Even, the abovementioned relationship remains effective irrespective of the left ventricular ejection fraction (LVEF), a most recent study by Sato showing an unaltered V̇O2peak prognostic power also in the early defined HF with mid-range ejection fraction class (HFmrEF).

Anemia is a highly prevalent comorbidity in heart failure (HF) patients and represents both a marker of HF severity and a predictor of poor prognosis.
Anemia is per se associated with impaired exercise performance and functional capacity.
Iron deficiency (ID) is an important comorbidity of HF, but the diagnosis and correction of ID remainlargely unrecognized in the cardiology community.

Objective: The use of dose-dense weekly chemotherapy in the management of advanced ovarian cancer (OC) remains controversial. The aim of this meta-analysis was to evaluate the efficacy of dose-dense regimen to improve clinical outcomes in OC patients with the inclusion of new trials.